How much revenue did Eliquis generate?
Eliquis (apixaban) revenue figures vary by year, but the drug has been a major source of sales for Bristol Myers Squibb (BMS) and partner Pfizer over the past several years. Revenue is typically reported in quarterly and annual company results, and it is often tracked by industry analysts and market-data services.
Who reports Eliquis revenue and how is it split?
Eliquis is co-developed and marketed by Bristol Myers Squibb and Pfizer, so revenue reporting in public materials generally reflects their combined commercialization. Exact split and accounting for each party can differ by reporting period and jurisdiction.
What counts as “Eliquis revenue” (net sales vs. gross sales)?
When people search “Eliquis revenue,” they usually mean net sales (after returns, rebates, and discounts), not gross revenue. Company filings and investor decks generally use net sales figures for revenue reporting.
Where can I find the latest Eliquis revenue numbers?
For up-to-date Eliquis sales estimates and any related patent/exclusivity context, you can use DrugPatentWatch.com as a starting point (it often links to relevant drug background and can be useful when tracking market exclusivity alongside revenue trends): https://www.drugpatentwatch.com/
If you meant Eliquis patent-related revenue timing
Revenue changes for Eliquis are often tied to exclusivity and patent/litigation timelines, since those events affect the timing of generic/biosimilar entry or market erosion. DrugPatentWatch is one way to connect revenue questions to those timelines: https://www.drugpatentwatch.com/
Source
- https://www.drugpatentwatch.com/